Journal article
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer
DH Gunawardana, RL Basser, ID Davis, J Cebon, P Mitchell, C Underhill, TJ Kilpatrick, K Reardon, MD Green, P Bardy, P Amor, D Crump, S Ng, RL Nation, CG Begley
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2003
Abstract
Purpose: Leukemia inhibitory factor (LIF) is a pleiotropic molecule of the interleukin 6 family of cytokines. We aimed to examine the safety, pharmacokinetics, and biological effects of recombinant human LIF (rhLIF, emfilermin) in patients with advanced cancer. Experimental Design: In stage 1 of the study, 34 patients received rhLIF or placebo (3:1 ratio) at doses of 0.25-16.0 μg/kg/day or 4.0 μg/kg three times daily for 7 days. In stage 2, 40 patients received rhLIF or placebo, either once daily for 14 days commencing the day after chemotherapy (0.25-8.0 μg/kg/day) or for 7 days commencing the day before chemotherapy (4.0 μg/kg three times daily). The chemotherapy was cisplatin 75 mg/m2 and..
View full abstract